- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01089595
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Open Label Phase II Randomized Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or in Combination With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced GIST That Have Progressed on High Dose Imatinib
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Resistance to imatinib does develop and represents a major clinical challenge. Mechanisms implicated in imatinib resistance include: target resistance due to new KIT or PDGFRA mutations or over expression of the KIT protein; target modulation due to activation of an alternate receptor tyrosine kinase protein with loss of KIT oncoprotein expression; functional resistance due to KIT or PDGFRA activation without a secondary mutation; and alterations in imatinib uptake by P-glycoprotein.
This study seeks to test nilotinib alone and nilotinib in combination with imatinib in patients that have progressed on imatinib.
Nilotinib is a new synthetic second-generation inhibitor of the BCR-ABL tyrosine kinase that competes for the ATP-bindings sites of BCR-ABL. A completed phase I trial assessed the activity of nilotinib alone and in combination with imatinib in patients that have progressed on imatinib in a population of patients with imatinib refractory and intolerant patients. There were rare responses, but stable disease was observed in grater than 50% of patients.
This study is aiming to treat patients with advanced or metastatic GIST who have disease progression on imatinib dose escalated up to 600 mg or greater. The rationale for exploring Nilotinib in this setting is to determine if it has therapeutic efficacy, with potentially less toxicity than the current standard of care for second line therapy. In addition, since it is not uncommon to see progression of some metastatic GIST lesions on imatinib, while others remain controlled, adding nilotinib may treat the progressing lesions while imatinib continues to control the areas without disease progression.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Siteman Cancer Center, Washington University School of Mediciine
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157-1082
- Wake Forest University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- histologically or cytologically confirmed GIST.
- advanced/metastatic GIST.
- experienced failure of prior treatment with imatinib 600-800 mg per day defined by progression of disease according to RECIST criteria during treatment. Radiographic evidence of PD on imatinib must be confirmed by the Investigator prior to enrollment.
- May have focal progression of disease including a new enhancing nodular focus within a pre-existing tumor nodule; such a nodule should be considered measurable by standard RECIST criteria.
- measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan.
- At least 4 weeks since prior therapy with imatinib & resolution of all acute toxic effects of the prior therapy or surgical procedure to grade ≤1.
- Age >18 years.
- ECOG performance status 0-2.
Normal organ and marrow function as defined below:
- ANC >1,500/mcL
- Platelets >100,000/mcL
- Total bilirubin < or equal to 1.5 X ULN
- AST(SGOT)/ALT(SGPT) < or equal to 2.5 X ULN OR < or equal to 5.0 X ULN if considered due to tumor
- Amylase/Lipase < or equal to 1.5 X ULN
- Alkaline Phosphatase < or equal to 2.5 X ULN or </= 5 X ULN if considered tumor related.
- Potassium, magnesium, calcium, phosphorus, creatinine WNL prior to randomization
- OR
- Creatinine clearance of > 50 calculated by cockroft-gault formula
- WOCBP must have negative pregnancy test within 7 days of first treatment and use appropriate contraception.
- Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
- Have received nilotinib or additional tyrosine kinase inhibitors or additional targeted therapies (except for imatinib).
- May not be receiving any other investigational agents within 4 weeks before treatment.
- Prior or concomitant malignancies (with a relapse in the last 5 years or requiring active treatment) other than GIST and with exception of previous or concomitant basal cell skin, previous cervical carcinoma in situ.
- Impaired cardiac function, including any one of the following:
Complete left bundle branch block. Ventricular paced cardiac pacemaker. Congenital long QT syndrome or family history of long QT syndrome. History of or presence of symptomatic ventricular or atrial tachyarrhythmias. Clinically significant resting bradycardia (< 50 beats per minute). QTc > 480 msec on screening ECG (using the QTcF formula). If QTc > 480 msec and electrolytes are not within normal ranges (electrolytes should be corrected and then the patient rescreened for QTc).
Right bundle branch block plus left anterior hemiblock, bifascicular block. Myocardial infarction within 12 months prior to Visit 1. Other clinically significant heart diseases (e.g., unstable angina, congestive heart failure or uncontrolled hypertension).
Severe and/or uncontrolled concurrent medical disease that could cause unacceptable safety risks or compromise compliance with protocol e.g. impairment of GI function, or GI disease that may significantly alter absorption of study drugs; uncontrolled diabetes; active infections; psychiatric illness/social situation that would limit compliance with study requirements.
- Inability to remain laying down in PET scanner for up to one hour.
- Use of any medications that prolong the QT interval and CYP3A4 inhibitors if treatment cannot be either safely discontinued or switched to a different medication prior to starting study drug administration.
- Major surgery ≤ 2 weeks prior to Visit 1 or who have not recovered from side effects of such surgery.
- Known history of noncompliance to medical regimens or inability/unwillingness to return for scheduled visits, patients who are pregnant or breast feeding, patients unwilling or unable to comply with the requirements for the protocol.
- Known chronic liver disease (i.e., chronic active, hepatitis, and cirrhosis).
- Known diagnosis of HIV, currently taking combination antiretroviral therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nilotinib
Nilotinib 400 mg po bid
|
Nilotinib 400 mg po bid
Other Names:
|
Active Comparator: Nilotinib + Imatinib
Nilotinib 400 mg BID with Imatinib 400 mg daily
|
Nilotinib 400 mg po BID Imatinib 400 mg po daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: 6 months until death or for 5 years
|
Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression.
It will be determined for both RECIST (Response Evaluation Criteria in Solid Tumors) and CHOI criteria.
|
6 months until death or for 5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Best Overall Response Using Response Evaluation Criteria in Solid Tumors, Choi Criteria, and Positron Emission Tomography Imaging
Time Frame: Every 8 weeks for up to 5 years
|
Every 8 weeks for up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FER-SAR-023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Disease
-
Memorial Sloan Kettering Cancer CenterCompletedMetastatic Solid Tumors of Metastatic DiseaseUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawnMetastatic Disease to Bone | Metastatic Disease to Soft TissueUnited States
-
M.D. Anderson Cancer CenterNot yet recruitingOligoProgressive Metastatic DiseaseUnited States
-
Institut CurieUnknownReccurent/Metastatic Solid Tumor DiseaseFrance
-
Washington University School of MedicineVarian Medical SystemsCompletedIntracranial Metastatic Disease From Any Solid MalignancyUnited States
-
University of California, San DiegoActive, not recruitingMetastatic CancerUnited States
-
Duke UniversityRecruitingMetastatic Cancer | OligometastasisUnited States
-
The Cooper Health SystemCompletedCancer | Metastatic CancerUnited States
-
The Leeds Teaching Hospitals NHS TrustCompletedMetastatic Spinal Disease
-
Maastricht Radiation OncologyKarolinska Institutet; KU Leuven; Maastricht University Medical Center; Catholic... and other collaboratorsWithdrawnNSCLC Stage IV | Limited Metastatic DiseaseNetherlands
Clinical Trials on Nilotinib
-
Niguarda HospitalCompletedLeukemia, Myeloid, Chronic-PhaseItaly
-
Novartis PharmaceuticalsTerminatedPulmonary Arterial HypertensionSwitzerland, United States, Germany, Singapore, Korea, Republic of, Canada
-
Georgetown UniversityUnknownParkinson Disease | Parkinsons Disease With DementiaUnited States
-
XSpray MicroparticlesCompleted
-
KeifeRx, LLCWorldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...Not yet recruiting
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaboratorsRecruitingChronic Myeloid Leukemia, Chronic Phase | NilotinibChina
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalActive, not recruitingTenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell TumorUnited States
-
Novartis PharmaceuticalsNo longer availableHypereosinophilic Syndrome (HES)
-
Novartis PharmaceuticalsNo longer availableAcute Lymphoblastic Leukemia (ALL)
-
Novartis PharmaceuticalsCompleted